We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck & Other Pharma Players Await FDA Decisions in October
Read MoreHide Full Article
In the United States, there has been a huge increase in FDA approvals for cancer and rare- to-treat diseases’ drugs, thanks to efficient and effective regulatory processes. The FDA has already approved 41 novel drugs till September. Last year, the FDA had given nod to 34 new drugs till September and approved 46 drugs in the full year.
The 46 drug approvals last year were the highest number of drugs approved by the FDA in more than a decade. Looking at the trend this year so far, it appears that the number of drug approvals will easily surpass 2017’s tally. With President Trump supporting streamlined FDA policies with an expedited drug approval process, innovation has picked up pace in the sector, thus increasing the possibility of approvals.
Landmark decisions this year so far include J&J’s (JNJ - Free Report) Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals’ cystic fibrosis (CF) medicine Symdeko; Amgen (AMGN - Free Report) /Novartis (NVS - Free Report) , Eli Lilly (LLY - Free Report) and Teva Pharma’s (TEVA - Free Report) calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie’s (ABBV - Free Report) Orilissa for pain associated with endometriosis; Merck’s (MRK - Free Report) two new HIV drugs — Pifeltro and Delstrigo; and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU).
The drug development process is lengthy and requires a lot of funds and resources. Consequently, pipeline events including data readouts and regulatory updates act as major catalysts.
Let’s take a look at a few important regulatory events scheduled for the month of October.
FDA Decision on Merck’s Keytruda for a Difficult Lung Cancer: On Oct 30, the FDA is expected to give its decision on Merck’s sNDA seeking label expansion of Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC)— a difficult-to-treat lung cancer patient population. The sNDA filing was based on data from the phase 3 KEYNOTE-407 study.
Data from the study presented at ASCO showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival (OS) and progression-free survival regardless of PD-L1 expression. The data was termed “practice changing” by CNBC – changing the way doctors look at prescribing these drugs to cancer patients. If Merck gets approval for this label expansion, it will further cement its position in the lung cancer market, which is the most lucrative oncology sector.
New Indication for Regeneron/Sanofi’s Dupixent: On Oct 20, the FDA is expected to give its decision on Regeneron/Sanofi’s supplemental biologics license application (sBLA) for label expansion of its eczema drug, Dupixent for a new indication – as an add-on maintenance treatment of adults and adolescents with moderate-to-severe asthma.
Dupixent is already approved for the treatment of atopic dermatitis (AD) or eczema. Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases such as nasal polyposis, eosinophilic esophagitis and grass immunotherapy.
Approval of Roche’s and Jazz Pharmaceuticals’ Drugs in Expanded Patient Populations: This week, a decision is expected on Roche’s sBLA seeking approval of its drug Hemlibra for treatment of hemophilia A patients without factor VIII inhibitors. Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors.
On Oct 27, the FDA is expected to give its decision on Jazz Pharmaceuticals’ sNDA, looking for approval of its key drug Xyrem in pediatric patients for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
Ionis Pharma’s Tegsedi and Therapeutics MD’s TX-001HR Await FDA Nod: The FDA will give its decision on Akcea Therapeutics and Ionis Pharmaceuticals’ Tegsedi (inotersen) on Oct 6. Tegsedi has been developed for the treatment of hereditary TTR amyloidosis (hATTR), an inherited, progressive and fatal disease with limited treatment options. Tegsedi was approved in the European Union in July this year.
On Oct 28, the FDA is expected to give its decision on TherapeuticsMD’s pipeline candidate TX-001HR, a bio-identical hormone therapy combination of estradiol and progesterone. TherapeuticsMD is seeking approval of TX-001HR as a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
FDA Approval of Bausch Health’s Jemdel Lotion Due: On Oct 5, the FDA is expected to give its decision on Bausch Health Companies’ high-potency topical steroid treatment, Jemdel for plaque psoriasis.
Stay Tuned for Additional Updates
Some key FDA decisions expected in the near term include Acorda Therapeutics’ Inbrija for treating OFF periods in patients with Parkinson’s disease (PD), Sanofi’s sotagliflozin for type I diabetes, Alexion’s ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and Jazz Pharmaceuticals’ solriamfetol for excessive sleepiness in narcolepsy & obstructive sleep apnea among others. Hence, investors are expected to keep a close watch on the FDA’s actions in the next few months
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Merck & Other Pharma Players Await FDA Decisions in October
In the United States, there has been a huge increase in FDA approvals for cancer and rare- to-treat diseases’ drugs, thanks to efficient and effective regulatory processes. The FDA has already approved 41 novel drugs till September. Last year, the FDA had given nod to 34 new drugs till September and approved 46 drugs in the full year.
The 46 drug approvals last year were the highest number of drugs approved by the FDA in more than a decade. Looking at the trend this year so far, it appears that the number of drug approvals will easily surpass 2017’s tally. With President Trump supporting streamlined FDA policies with an expedited drug approval process, innovation has picked up pace in the sector, thus increasing the possibility of approvals.
Landmark decisions this year so far include J&J’s (JNJ - Free Report) Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals’ cystic fibrosis (CF) medicine Symdeko; Amgen (AMGN - Free Report) /Novartis (NVS - Free Report) , Eli Lilly (LLY - Free Report) and Teva Pharma’s (TEVA - Free Report) calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie’s (ABBV - Free Report) Orilissa for pain associated with endometriosis; Merck’s (MRK - Free Report) two new HIV drugs — Pifeltro and Delstrigo; and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU).
The drug development process is lengthy and requires a lot of funds and resources. Consequently, pipeline events including data readouts and regulatory updates act as major catalysts.
Let’s take a look at a few important regulatory events scheduled for the month of October.
FDA Decision on Merck’s Keytruda for a Difficult Lung Cancer: On Oct 30, the FDA is expected to give its decision on Merck’s sNDA seeking label expansion of Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC)— a difficult-to-treat lung cancer patient population. The sNDA filing was based on data from the phase 3 KEYNOTE-407 study.
Data from the study presented at ASCO showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival (OS) and progression-free survival regardless of PD-L1 expression. The data was termed “practice changing” by CNBC – changing the way doctors look at prescribing these drugs to cancer patients. If Merck gets approval for this label expansion, it will further cement its position in the lung cancer market, which is the most lucrative oncology sector.
New Indication for Regeneron/Sanofi’s Dupixent: On Oct 20, the FDA is expected to give its decision on Regeneron/Sanofi’s supplemental biologics license application (sBLA) for label expansion of its eczema drug, Dupixent for a new indication – as an add-on maintenance treatment of adults and adolescents with moderate-to-severe asthma.
Dupixent is already approved for the treatment of atopic dermatitis (AD) or eczema. Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases such as nasal polyposis, eosinophilic esophagitis and grass immunotherapy.
Approval of Roche’s and Jazz Pharmaceuticals’ Drugs in Expanded Patient Populations: This week, a decision is expected on Roche’s sBLA seeking approval of its drug Hemlibra for treatment of hemophilia A patients without factor VIII inhibitors. Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors.
On Oct 27, the FDA is expected to give its decision on Jazz Pharmaceuticals’ sNDA, looking for approval of its key drug Xyrem in pediatric patients for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
Ionis Pharma’s Tegsedi and Therapeutics MD’s TX-001HR Await FDA Nod: The FDA will give its decision on Akcea Therapeutics and Ionis Pharmaceuticals’ Tegsedi (inotersen) on Oct 6. Tegsedi has been developed for the treatment of hereditary TTR amyloidosis (hATTR), an inherited, progressive and fatal disease with limited treatment options. Tegsedi was approved in the European Union in July this year.
On Oct 28, the FDA is expected to give its decision on TherapeuticsMD’s pipeline candidate TX-001HR, a bio-identical hormone therapy combination of estradiol and progesterone. TherapeuticsMD is seeking approval of TX-001HR as a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
FDA Approval of Bausch Health’s Jemdel Lotion Due: On Oct 5, the FDA is expected to give its decision on Bausch Health Companies’ high-potency topical steroid treatment, Jemdel for plaque psoriasis.
Stay Tuned for Additional Updates
Some key FDA decisions expected in the near term include Acorda Therapeutics’ Inbrija for treating OFF periods in patients with Parkinson’s disease (PD), Sanofi’s sotagliflozin for type I diabetes, Alexion’s ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and Jazz Pharmaceuticals’ solriamfetol for excessive sleepiness in narcolepsy & obstructive sleep apnea among others. Hence, investors are expected to keep a close watch on the FDA’s actions in the next few months
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>